Illustrative peptide vials labeled GLP, BPC-157, and TB-500Peptide LegalCompliance Help and DefenseRequest review →

Scope of practice · Referrals · Integrated clinics

A peptide program can cross a licensing boundary.

Before offering, administering, selling, or promoting a peptide service, establish exactly what your license and business structure authorize.

Chiropractors  •  Updated September 24, 2026  •  4-minute read

AI-generated chiropractor adjusting a patient, with vials in the background
AI-generated illustration. Not an actual client, provider, or endorsement.

A chiropractic office may be approached with an apparently simple offer: add a peptide program, use a medical partner, or receive referral compensation. Each arrangement raises different questions. A licensed clinician’s presence does not answer who is practicing, who controls care, who supplies the product, or whether the financial arrangement is permitted.

Key distinctionLouisiana example: R.S. 37:2801(3)(c) excludes prescribing, dispensing, and administering medicine or drugs from chiropractic practice. Its listed exclusions from “medicine” and “drugs” should not be assumed to authorize injectable peptides. Other states require their own analysis. [1]
01 / RISK OVERVIEW

Professional exposure

Scope-of-practice complaints and questions about supervision, titles, referrals, or advertising.

02 / RISK OVERVIEW

Civil exposure

Patient claims, consent disputes, misleading representations, and business-partner disagreements.

03 / RISK OVERVIEW

Criminal exposure

Drug-law or unlawful-practice allegations may require criminal counsel; the applicable law and conduct control.

Define each person’s role before launching

Who evaluates the patient? Who makes the treatment decision? Who orders, stores, sells, and administers the product? Who receives the fee? Put the real workflow on paper. Counsel should compare it with the law of the state where the patient receives care, each professional’s license, and the contracts between the practice and any medical partner.

A referral arrangement needs its own review

Paying for marketing, sharing office space, employing professionals, and receiving a percentage of treatment revenue are different arrangements. State ownership and fee-splitting rules, and federal referral restrictions where applicable, require fact-specific assessment. Calling a payment a consulting fee does not settle its legal character. Have counsel review the actual services and compensation before relying on a template agreement.

Civil and criminal issues are not interchangeable

A patient may allege that the office overstated benefits, failed to explain material risks, or provided care outside an authorized role. A board complaint is a separate process and is not proof of a criminal offense. Section 333 provides criminal penalties for prohibited drug-law conduct, including enhanced penalties for certain repeat offenses or intent to defraud or mislead. [3]

How an attorney can help protect the practice

Counsel can assess whether the proposed service should proceed, change, or stop; review professional roles and compensation; coordinate a response to a board; and evaluate patient complaints or insurance obligations. Legal review should occur before adding the offering to a treatment menu. It cannot replace the medical judgment or licensing authority of the treating professional.

PRACTICAL NEXT STEPS

Prepare for a useful legal consultation.

  1. Collect the actual treatment workflow, licenses, agreements, advertisements, and compensation terms.
  2. Preserve complaint and patient records; do not alter historical entries or messages.
  3. Request review in each relevant state before relying on a medical-partner or referral model.

Get advice for your specific situation.

Request a free initial consultation through our preliminary review form. Counsel can assess the facts, jurisdiction, urgency, and whether representation can be offered.

Start your review →

Sources & scope

Primary sources reviewed September 24, 2026. The discussion applies these sources to common business scenarios; it is not an agency ruling on your business. Rules, enforcement policies, and product status can change. State-specific questions require current local-law review.

  1. Louisiana Legislature: R.S. 37:2801, chiropractic scope
  2. FDA: Unapproved GLP-1 drug concerns
  3. U.S. Code: 21 U.S.C. 333 — criminal penalties